Here we utilized Etrasimod, a fully functional antagonist of mouse and human S1P1 and partial S1P4 and S1P5 antagonist (11), and Amiselimod, a functional S1P1 antagonist (12), to examine the effects of S1P receptor pharmacological inhibition on the intrahepatic leukocyte populations associated with NASH. Here, S1PR5 is linked to metabolic dysfunction-associated steatohepatitis.